Hikma Pharmaceuticals Plc (HIK) Downgraded by Morgan Stanley
Hikma Pharmaceuticals Plc (LON:HIK) was downgraded by equities research analysts at Morgan Stanley to an “equal weight” rating in a report released on Monday. They presently have a GBX 1,350 ($17.53) target price on the stock, down from their prior target price of GBX 1,600 ($20.77). Morgan Stanley’s target price would suggest a potential upside of 4.81% from the company’s previous close.
Other equities analysts have also issued reports about the stock. Numis Securities Ltd reissued an “add” rating and issued a GBX 2,000 ($25.96) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Peel Hunt reissued a “hold” rating and issued a GBX 2,150 ($27.91) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 17th. Jefferies Group LLC dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.04) to GBX 1,045 ($13.57) and set a “hold” rating on the stock in a research report on Monday. J P Morgan Chase & Co reissued a “neutral” rating and issued a GBX 1,500 ($19.47) price objective (down from GBX 1,800 ($23.37)) on shares of Hikma Pharmaceuticals Plc in a research report on Monday, May 22nd. Finally, Citigroup Inc. reissued a “neutral” rating and issued a GBX 1,550 ($20.12) price objective on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,686 ($21.89).
Hikma Pharmaceuticals Plc (LON HIK) traded up 4.12% during trading on Monday, reaching GBX 1288.00. 939,312 shares of the company’s stock were exchanged. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,101.00 and a 1-year high of GBX 2,346.00. The company’s 50-day moving average is GBX 1,346.92 and its 200-day moving average is GBX 1,734.37. The company’s market capitalization is GBX 3.09 billion.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.